On August 25, Electromed (NASDAQ:ELMD) reported fiscal fourth-quarter results that extended a streak few small-cap medical device companies can claim: fifteen consecutive quarters of year-over-year revenue and profit growth. Net revenue hit a record $19.4 million, up 11.6% from a year earlier, and diluted earnings per share climbed to $0.39 from $0.25. Those headline numbers look clean, but they arrive alongside a leadership change and a hospital business moving in the opposite direction, which makes the quarter more complicated than the growth streak suggests.
Home care is still the whole story here. Home care revenue reached $17.7 million in the quarter, up 15.2% year over year, and for the full fiscal year it grew 16.3% to $66.6 million. That growth is coming from efficiency, not just headcount: on an annualized basis, home care revenue worked out to $1,145,000 per rep, above the company's own target range of $1 million to $1.1 million. Electromed ended the year with 64 direct sales reps and is targeting 67 filled territories for fiscal 2027, including two hospital account liaisons meant to catch patients as they move from acute care into home-based therapy.
The addressable market behind that growth still looks large. Management estimates roughly 1 million people in the U.S. carry a bronchiectasis diagnosis, yet only about 16% currently use high-frequency chest wall oscillation therapy, leaving close to 800,000 diagnosed patients untreated, plus more than 4 million additional people who may have the condition without a diagnosis at all. Payer access has kept pace with that opportunity.
Electromed closed the fiscal year with 87% of US covered lives under contract after signing 40 new payer agreements and adding 6 million covered lives. Its Smart Order e-prescribing tool handled 45% of fourth-quarter orders and shipped them noticeably faster than fax submissions, which matters as CMS rules phase out fax-based ordering by May 2028. All of this sits on a debt-free balance sheet, with cash growing to $20.5 million even after $3.9 million in share repurchases during the year.
The weaker spots are easy to miss next to those numbers. Hospital revenue fell 29% in the fourth quarter, which CEO James Cunniff attributed to a sales cycle that is "inherently less predictable than our other channels." The distributor channel grew just 2% in the quarter, and combined, the non-home care business grew only 6.7% for the full year versus 16.3% in home care, meaning nearly all of Electromed's growth is coming from one channel. SG&A expenses rose 8.7% to $42.7 million for the year, driven mainly by higher sales, marketing, and reimbursement compensation, and accounts receivable climbed to $29.8 million from $24.7 million as the business scaled up.
#quarter #Growth #electromed #hospital
Home care is still the whole story here. Home care revenue reached $17.7 million in the quarter, up 15.2% year over year, and for the full fiscal year it grew 16.3% to $66.6 million. That growth is coming from efficiency, not just headcount: on an annualized basis, home care revenue worked out to $1,145,000 per rep, above the company's own target range of $1 million to $1.1 million. Electromed ended the year with 64 direct sales reps and is targeting 67 filled territories for fiscal 2027, including two hospital account liaisons meant to catch patients as they move from acute care into home-based therapy.
The addressable market behind that growth still looks large. Management estimates roughly 1 million people in the U.S. carry a bronchiectasis diagnosis, yet only about 16% currently use high-frequency chest wall oscillation therapy, leaving close to 800,000 diagnosed patients untreated, plus more than 4 million additional people who may have the condition without a diagnosis at all. Payer access has kept pace with that opportunity.
Electromed closed the fiscal year with 87% of US covered lives under contract after signing 40 new payer agreements and adding 6 million covered lives. Its Smart Order e-prescribing tool handled 45% of fourth-quarter orders and shipped them noticeably faster than fax submissions, which matters as CMS rules phase out fax-based ordering by May 2028. All of this sits on a debt-free balance sheet, with cash growing to $20.5 million even after $3.9 million in share repurchases during the year.
The weaker spots are easy to miss next to those numbers. Hospital revenue fell 29% in the fourth quarter, which CEO James Cunniff attributed to a sales cycle that is "inherently less predictable than our other channels." The distributor channel grew just 2% in the quarter, and combined, the non-home care business grew only 6.7% for the full year versus 16.3% in home care, meaning nearly all of Electromed's growth is coming from one channel. SG&A expenses rose 8.7% to $42.7 million for the year, driven mainly by higher sales, marketing, and reimbursement compensation, and accounts receivable climbed to $29.8 million from $24.7 million as the business scaled up.
#quarter #Growth #electromed #hospital
2 months ago
